Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor, volume II PDF Download
Are you looking for read ebook online? Search for your book and save it on your Kindle device, PC, phones or tablets. Download Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor, volume II PDF full book. Access full book title Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor, volume II by Xi Cheng. Download full books in PDF and EPUB format.
Author: Xi Cheng Publisher: Frontiers Media SA ISBN: 2832540821 Category : Medical Languages : en Pages : 213
Book Description
This Research Topic is the second volume of the “Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor". Please Volume I here. The microenvironment of tumors is consisted of the tumor stroma, proliferating tumor cells, infiltrating inflammatory cells, blood vessels, and various associated tissue cells. The pre-metastatic niche (PRN) is described as supportive and receptive, which undergoes cellular and molecular changes to form the fertile “soil” or metastatic-designated sites for metastatic tumor cell “seed” colonization. Thus, the PRN supports promoting tumor metastasis and tumor settlement in distant organs. The infiltration of the immune cells and the formation of blood vessels from the pre-metastatic sites are critical for the tumor microenvironment. Typically, the angiogenic factor is strongly associated with the inflammatory response during the development of tumors. Additionally, the immunoediting processes are essentially devoted to promoting angiogenesis and modulating the innate and specific immune responses.
Author: Xi Cheng Publisher: Frontiers Media SA ISBN: 2832540821 Category : Medical Languages : en Pages : 213
Book Description
This Research Topic is the second volume of the “Community Series in the Role of Angiogenesis and Immune Response in Tumor Microenvironment of Solid Tumor". Please Volume I here. The microenvironment of tumors is consisted of the tumor stroma, proliferating tumor cells, infiltrating inflammatory cells, blood vessels, and various associated tissue cells. The pre-metastatic niche (PRN) is described as supportive and receptive, which undergoes cellular and molecular changes to form the fertile “soil” or metastatic-designated sites for metastatic tumor cell “seed” colonization. Thus, the PRN supports promoting tumor metastasis and tumor settlement in distant organs. The infiltration of the immune cells and the formation of blood vessels from the pre-metastatic sites are critical for the tumor microenvironment. Typically, the angiogenic factor is strongly associated with the inflammatory response during the development of tumors. Additionally, the immunoediting processes are essentially devoted to promoting angiogenesis and modulating the innate and specific immune responses.
Author: Carolyn A. Staton Publisher: John Wiley & Sons ISBN: 047002934X Category : Medical Languages : en Pages : 410
Book Description
Angiogenesis, the development of new blood vessels from the existing vasculature, is essential for physiological growth and over 18,000 research articles have been published describing the role of angiogenesis in over 70 different diseases, including cancer, diabetic retinopathy, rheumatoid arthritis and psoriasis. One of the most important technical challenges in such studies has been finding suitable methods for assessing the effects of regulators of eh angiogenic response. While increasing numbers of angiogenesis assays are being described both in vitro and in vivo, it is often still necessary to use a combination of assays to identify the cellular and molecular events in angiogenesis and the full range of effects of a given test protein. Although the endothelial cell - its migration, proliferation, differentiation and structural rearrangement - is central to the angiogenic process, it is not the only cell type involved. the supporting cells, the extracellular matrix and the circulating blood with its cellular and humoral components also contribute. In this book, experts in the use of a diverse range of assays outline key components of these and give a critical appraisal of their strengths and weaknesses. Examples include assays for the proliferation, migration and differentiation of endothelial cells in vitro, vessel outgrowth from organ cultures, assessment of endothelial and mural cell interactions, and such in vivo assays as the chick chorioallantoic membrane, zebrafish, corneal, chamber and tumour angiogenesis models. These are followed by a critical analysis of the biological end-points currently being used in clinical trials to assess the clinical efficacy of anti-angiogenic drugs, which leads into a discussion of the direction future studies should take. This valuable book is of interest to research scientists currently working on angiogenesis in both the academic community and in the biotechnology and pharmaceutical industries. Relevant disciplines include cell and molecular biology, oncology, cardiovascular research, biotechnology, pharmacology, pathology and physiology.
Author: Luc Van Kaer Publisher: Frontiers Media SA ISBN: 2832554830 Category : Medical Languages : en Pages : 177
Book Description
This is the second volume in the series, the Role of CD1- and MR1-restricted T cells in Immunity and Disease. Please see volume I here. CD1 and MR1 are major histocompatibility complex (MHC) class I-related proteins that bind and present non-peptide antigens to subsets of T cells with specialized functions. CD1 proteins typically present lipid antigens to CD1-restricted T cells, whereas MR1 presents vitamin B-based ligands and a variety of drugs and drug-like molecules to MR1-restricted T cells. The CD1 family of antigen-presenting molecules has been divided into two groups: Group 1 contains CD1a, CD1b, and CD1c, and Group 2 contains CD1d. Additionally, CD1e is expressed intracellularly and is involved in the loading of lipid antigens onto Group 1 CD1 proteins. Humans express both Groups 1 and 2 CD1 proteins, whereas mice only express CD1d. Group 1 CD1 proteins present lipid antigens to T cells that generally express diverse T cell receptors (TCRs) and exhibit adaptive-like functions, whereas CD1d presents lipid antigens to subsets of T cells that express either diverse or highly restricted TCRs and exhibit innate-like functions. CD1d-restricted T cells are called natural killer T (NKT) cells, which include Type I or invariant NKT (iNKT) cells expressing semi-invariant TCRs, and Type II NKT cells expressing more diverse TCRs. CD1-restricted T cells have been implicated in a wide variety of diseases, including cancer, infections, and autoimmune, inflammatory, and metabolic diseases. Additionally, NKT cells have been targeted for immunotherapy of disease with ligands such as α or α-galactosylceramide for iNKT cells, or sulfatide for Type II NKT cells.
Author: Publisher: Frontiers Media SA ISBN: 2832541933 Category : Medical Languages : en Pages : 261
Book Description
This Research Topic is the second volume of the “Community Series in Novel Biomarkers for Predicting Response to Cancer Immunotherapy". Please see Volume I here. Immunotherapy has revolutionized the treatment of malignancies. Targeting of immune checkpoints cytotoxic T-lymphocyte-associated protein 4, programmed cell death protein 1 (PD-1) and its ligand (PD-L1) has led to improving survival in a subset of patients. Despite their remarkable success, clinical benefit remains limited to only a subset of patients. A significant limitation behind these current treatment modalities is an irregularity in clinical response, which is especially pronounced among checkpoint inhibition. Currently, relevant predictors of cancer immunotherapy response include microsatellite instability-high/deficient mismatch repair (MSI-H/dMMR), expression of PD-L1, tumor mutation burden (TMB), immune genomic characteristics, and tumor infiltrating lymphocytes (TILs). However, none of them have sufficient evidence to be a stratification factor. Moreover, as the combined strategies for effective cancer immunotherapy had been developed in multiple tumors, such as Immunotherapy combined with chemotherapy, radiotherapy, targeted therapy and anti-angiogenesis therapy. Therefore, the development of novel biomarkers endowed with high sensitivity, specificity and accuracy able to identify which patients may truly benefit from the treatment with cancer immunotherapy would allow to refine the therapeutic selection and to better tailor the treatment strategy. This research topic aims to focus on the advances in the discoveries of novel biomarkers for predicting response to cancer immunotherapy in various tumors. We welcome the submission of original research and review articles that include biomarkers in clinical study and applications, as well as technologies or discoveries in experimental approaches.
Author: Xi Cheng
Author: Xi Cheng
Author: Huanfa Yi
Author: Xiao Liang
Author: Carolyn A. Staton
Author: Luc Van Kaer 
Author: Ren Zhao
Author: Ping Zheng
Author: Chang Li
Author: 
Author: Jian Zhang